The scleroderma market size has grown strongly in recent years. It will grow from $2.15 billion in 2023 to $2.31 billion in 2024 at a compound annual growth rate (CAGR) of 7.4%. The growth in the historic period can be ascribed to progress in diagnostic methods, advancements in immunological research, developments in therapeutic approaches, increased awareness and education, and genetic studies.
The scleroderma market size is expected to see strong growth in the next few years. It will grow to $2.97 billion in 2028 at a compound annual growth rate (CAGR) of 6.5%. The anticipated growth in the forecast period can be credited to the emergence of biological therapies, advancements in precision medicine, the development of stem cell therapies, ongoing research in genomics and biomarkers, and increased global collaborations. Major trends expected in the forecast period include the adoption of digital health solutions, a heightened focus on the microbiome, a shift towards patient-centric care, advancements in regenerative medicine, and a stronger emphasis on health equity and access.
The increasing prevalence of scleroderma is propelling the scleroderma market forward. Scleroderma, characterized by abnormal collagen growth, is a chronic autoimmune disease triggered by an unregulated immune response, possibly influenced by various environmental factors. As the number of cases rises, the significance of enhanced diagnosis and treatment becomes apparent. Effective scleroderma therapeutics are crucial for managing the illness and alleviating symptoms by regulating the immune response and mitigating exposure to environmental risk factors. For instance, a report by Karger Publishers in June 2022 indicated that 19,000 people had scleroderma in the UK, and the global prevalence reached 2.5 million people. Additionally, a research article published by Oxford Academic Press in July 2021 revealed a global prevalence of 17.6 cases per 100,000 people and an incidence rate of 1.4 cases per 100,000 person-years. Hence, the increasing prevalence of scleroderma is a driving force in the scleroderma market.
The impact of toxin exposure is further propelling the scleroderma market. Toxin exposure involves contact or ingestion of harmful substances that can negatively affect biological systems. The scleroderma market plays a crucial role in addressing toxin exposure by advancing research, developing targeted therapies, and improving patient care for those affected by scleroderma, a condition with potential environmental and genetic triggers. For example, a report by Poison Control in January 2023, a U.S.-based national poison control system, revealed over 2.08 million human poison exposures, with 75.5% being unintentional, and children under six accounting for 37.0 poison exposures per 1,000 children in 2021. In contrast, the previous year, 2020, saw 83% of reported poison exposures deemed nontoxic by U.S. poison centers. Thus, the exposure to toxins continues to drive the scleroderma market.
The development of novel treatments is a prominent trend gaining traction in the scleroderma market. Leading companies in the market are actively engaged in creating innovative drugs to effectively manage symptoms and maintain their market position. For example, in April 2022, Tyr Pharma Inc., a biotherapeutics manufacturer based in the US, secured regulatory approval from the US Food and Drug Administration for its groundbreaking systemic sclerosis-related interstitial lung disease drug, efzofitimod. This First-in-class immunomodulator targets the neuropilin-2 (NRP2) receptor to downregulate and control the immune response, offering relief from scleroderma symptoms. Moreover, efzofitimod demonstrated efficacy in reducing pro-inflammatory markers in a clinical study involving patients with pulmonary sarcoidosis, further highlighting its potential impact.
Major companies operating in the scleroderma market are emphasizing product launches, including a clinical trial platform, to advance scleroderma treatments and identify promising agents for progression from Phase IIb to Phase III. A clinical trial platform serves as a comprehensive infrastructure facilitating the concurrent assessment of multiple therapies across various clinical trials. In August 2023, The Scleroderma Research Foundation (SRF), a non-profit organization based in the US, introduced CONQUEST, a groundbreaking clinical trial platform. With a global reach spanning 130 centers in 22 countries, CONQUEST employs a master protocol to evaluate multiple therapies simultaneously. This initiative is poised to significantly impact the scleroderma market by accelerating the development and approval of effective therapies through its collaborative and efficient clinical evaluation approach.
In November 2021, Sanofi S.A., a pharmaceutical company based in France, completed the acquisition of Kadmon Holdings for approximately $1.9 billion. This strategic move aims to enhance Sanofi's medicine business and better cater to its customer base. Additionally, Sanofi plans to continue the development of Belumosudil, Kadmon's investigational therapy for treating diffuse cutaneous systemic sclerosis (dcSSc). Kadmon Holdings, based in the US, specializes in discovering, developing, and marketing transformative medicines for disease areas with significant unmet medical needs.
Major companies operating in the scleroderma market report are Pfizer Inc., Johnson And Johnson Inc., F. Hoffmann-La Roche AG, AbbVie Inc., Bayer AG, Novartis AG, Merck And Co. Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., GSK plc, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Aspen Pharmacare Holdings Limited, Boehringer Ingelheim International GmbH, Principia Biopharma Corp, aTyr Pharma Inc., Cumberland Pharmaceuticals Inc., Kadmon Holdings Inc., Emerald Health Pharmaceuticals Inc., FibroGen Inc., Argentis Pharmaceuticals LLC, Corbus Pharmaceuticals Holdings Inc., Celgene Corporation, Actelion Pharmaceuticals Inc., H.A.C. Pharma.
North America was the largest region in the scleroderma market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the scleroderma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the scleroderma market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.
The primary treatments for scleroderma encompass medication, surgery, and other therapeutic approaches. Medication involves the use of substances, typically in the form of drugs or pharmaceuticals, intended to prevent, treat, or manage medical conditions, diseases, or symptoms. Hospitals, pharmaceutical stores, and other healthcare providers commonly administer medications, specifically indicated for treating both systemic scleroderma and localized scleroderma.
The scleroderma market research report is one of a series of new reports that provides scleroderma market statistics, including scleroderma industry global market size, regional shares, competitors with a scleroderma market share, detailed scleroderma market segments, market trends and opportunities, and any further data you may need to thrive in the scleroderma industry. This scleroderma market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The scleroderma market consists of revenues earned by entities by providing dilation of blood vessels, immunosuppressants, relieving pain, and reducing infection. The market value includes the value of related goods sold by the service provider or included within the service offering. The scleroderma market also includes the sales of methotrexate, anti-thymocyte globulin, mycophenolate mofetil, and cyclophosphamide. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The scleroderma market size is expected to see strong growth in the next few years. It will grow to $2.97 billion in 2028 at a compound annual growth rate (CAGR) of 6.5%. The anticipated growth in the forecast period can be credited to the emergence of biological therapies, advancements in precision medicine, the development of stem cell therapies, ongoing research in genomics and biomarkers, and increased global collaborations. Major trends expected in the forecast period include the adoption of digital health solutions, a heightened focus on the microbiome, a shift towards patient-centric care, advancements in regenerative medicine, and a stronger emphasis on health equity and access.
The increasing prevalence of scleroderma is propelling the scleroderma market forward. Scleroderma, characterized by abnormal collagen growth, is a chronic autoimmune disease triggered by an unregulated immune response, possibly influenced by various environmental factors. As the number of cases rises, the significance of enhanced diagnosis and treatment becomes apparent. Effective scleroderma therapeutics are crucial for managing the illness and alleviating symptoms by regulating the immune response and mitigating exposure to environmental risk factors. For instance, a report by Karger Publishers in June 2022 indicated that 19,000 people had scleroderma in the UK, and the global prevalence reached 2.5 million people. Additionally, a research article published by Oxford Academic Press in July 2021 revealed a global prevalence of 17.6 cases per 100,000 people and an incidence rate of 1.4 cases per 100,000 person-years. Hence, the increasing prevalence of scleroderma is a driving force in the scleroderma market.
The impact of toxin exposure is further propelling the scleroderma market. Toxin exposure involves contact or ingestion of harmful substances that can negatively affect biological systems. The scleroderma market plays a crucial role in addressing toxin exposure by advancing research, developing targeted therapies, and improving patient care for those affected by scleroderma, a condition with potential environmental and genetic triggers. For example, a report by Poison Control in January 2023, a U.S.-based national poison control system, revealed over 2.08 million human poison exposures, with 75.5% being unintentional, and children under six accounting for 37.0 poison exposures per 1,000 children in 2021. In contrast, the previous year, 2020, saw 83% of reported poison exposures deemed nontoxic by U.S. poison centers. Thus, the exposure to toxins continues to drive the scleroderma market.
The development of novel treatments is a prominent trend gaining traction in the scleroderma market. Leading companies in the market are actively engaged in creating innovative drugs to effectively manage symptoms and maintain their market position. For example, in April 2022, Tyr Pharma Inc., a biotherapeutics manufacturer based in the US, secured regulatory approval from the US Food and Drug Administration for its groundbreaking systemic sclerosis-related interstitial lung disease drug, efzofitimod. This First-in-class immunomodulator targets the neuropilin-2 (NRP2) receptor to downregulate and control the immune response, offering relief from scleroderma symptoms. Moreover, efzofitimod demonstrated efficacy in reducing pro-inflammatory markers in a clinical study involving patients with pulmonary sarcoidosis, further highlighting its potential impact.
Major companies operating in the scleroderma market are emphasizing product launches, including a clinical trial platform, to advance scleroderma treatments and identify promising agents for progression from Phase IIb to Phase III. A clinical trial platform serves as a comprehensive infrastructure facilitating the concurrent assessment of multiple therapies across various clinical trials. In August 2023, The Scleroderma Research Foundation (SRF), a non-profit organization based in the US, introduced CONQUEST, a groundbreaking clinical trial platform. With a global reach spanning 130 centers in 22 countries, CONQUEST employs a master protocol to evaluate multiple therapies simultaneously. This initiative is poised to significantly impact the scleroderma market by accelerating the development and approval of effective therapies through its collaborative and efficient clinical evaluation approach.
In November 2021, Sanofi S.A., a pharmaceutical company based in France, completed the acquisition of Kadmon Holdings for approximately $1.9 billion. This strategic move aims to enhance Sanofi's medicine business and better cater to its customer base. Additionally, Sanofi plans to continue the development of Belumosudil, Kadmon's investigational therapy for treating diffuse cutaneous systemic sclerosis (dcSSc). Kadmon Holdings, based in the US, specializes in discovering, developing, and marketing transformative medicines for disease areas with significant unmet medical needs.
Major companies operating in the scleroderma market report are Pfizer Inc., Johnson And Johnson Inc., F. Hoffmann-La Roche AG, AbbVie Inc., Bayer AG, Novartis AG, Merck And Co. Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., GSK plc, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Aspen Pharmacare Holdings Limited, Boehringer Ingelheim International GmbH, Principia Biopharma Corp, aTyr Pharma Inc., Cumberland Pharmaceuticals Inc., Kadmon Holdings Inc., Emerald Health Pharmaceuticals Inc., FibroGen Inc., Argentis Pharmaceuticals LLC, Corbus Pharmaceuticals Holdings Inc., Celgene Corporation, Actelion Pharmaceuticals Inc., H.A.C. Pharma.
North America was the largest region in the scleroderma market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the scleroderma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the scleroderma market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.
The primary treatments for scleroderma encompass medication, surgery, and other therapeutic approaches. Medication involves the use of substances, typically in the form of drugs or pharmaceuticals, intended to prevent, treat, or manage medical conditions, diseases, or symptoms. Hospitals, pharmaceutical stores, and other healthcare providers commonly administer medications, specifically indicated for treating both systemic scleroderma and localized scleroderma.
The scleroderma market research report is one of a series of new reports that provides scleroderma market statistics, including scleroderma industry global market size, regional shares, competitors with a scleroderma market share, detailed scleroderma market segments, market trends and opportunities, and any further data you may need to thrive in the scleroderma industry. This scleroderma market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The scleroderma market consists of revenues earned by entities by providing dilation of blood vessels, immunosuppressants, relieving pain, and reducing infection. The market value includes the value of related goods sold by the service provider or included within the service offering. The scleroderma market also includes the sales of methotrexate, anti-thymocyte globulin, mycophenolate mofetil, and cyclophosphamide. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Scleroderma Market Characteristics3. Scleroderma Market Trends and Strategies32. Global Scleroderma Market Competitive Benchmarking33. Global Scleroderma Market Competitive Dashboard34. Key Mergers and Acquisitions in the Scleroderma Market
4. Scleroderma Market - Macro Economic Scenario
5. Global Scleroderma Market Size and Growth
6. Scleroderma Market Segmentation
7. Scleroderma Market Regional and Country Analysis
8. Asia-Pacific Scleroderma Market
9. China Scleroderma Market
10. India Scleroderma Market
11. Japan Scleroderma Market
12. Australia Scleroderma Market
13. Indonesia Scleroderma Market
14. South Korea Scleroderma Market
15. Western Europe Scleroderma Market
16. UK Scleroderma Market
17. Germany Scleroderma Market
18. France Scleroderma Market
19. Italy Scleroderma Market
20. Spain Scleroderma Market
21. Eastern Europe Scleroderma Market
22. Russia Scleroderma Market
23. North America Scleroderma Market
24. USA Scleroderma Market
25. Canada Scleroderma Market
26. South America Scleroderma Market
27. Brazil Scleroderma Market
28. Middle East Scleroderma Market
29. Africa Scleroderma Market
30. Scleroderma Market Competitive Landscape and Company Profiles
31. Scleroderma Market Other Major and Innovative Companies
35. Scleroderma Market Future Outlook and Potential Analysis
36. Appendix
Executive Summary
Scleroderma Global Market Report 2024 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on scleroderma market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
- Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
- Assess the Russia-Ukraine war’s impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
- Measure the impact of high global inflation on market growth.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis.
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for scleroderma? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? This report answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.
- The impact of higher inflation in many countries and the resulting spike in interest rates.
- The continued but declining impact of COVID-19 on supply chains and consumption patterns.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Report Scope
Markets Covered:1) By Treatment: Medication; Surgery; Other Treatments
2) By Indication: Systemic Scleroderma; Localized Scleroderma
3) By End-user: Hospital; Pharmaceutical Stores; Other End-users
Key Companies Mentioned: Pfizer Inc.; Johnson and Johnson Inc.; F. Hoffmann-La Roche AG; Abbvie Inc.; Bayer AG
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes
Delivery Format: PDF, Word and Excel Data Dashboard
Companies Mentioned
- Pfizer Inc.
- Johnson And Johnson Inc.
- F. Hoffmann-La Roche AG
- Abbvie Inc.
- Bayer AG
- Novartis AG
- Merck And Co. Inc.
- Sanofi S.A.
- Bristol-Myers Squibb Company
- AstraZeneca plc
- Takeda Pharmaceutical Company Limited
- Eli Lilly and Company
- Gilead Sciences Inc.
- Amgen Inc.
- GSK plc
- Teva Pharmaceutical Industries Ltd.
- Astellas Pharma Inc.
- Aspen Pharmacare Holdings Limited
- Boehringer Ingelheim International GmbH
- Principia Biopharma Corp
- aTyr Pharma Inc.
- Cumberland Pharmaceuticals Inc.
- Kadmon Holdings Inc.
- Emerald Health Pharmaceuticals Inc.
- FibroGen Inc.
- Argentis Pharmaceuticals LLC
- Corbus Pharmaceuticals Holdings Inc.
- Celgene Corporation
- Actelion Pharmaceuticals Inc.
- H.A.C. Pharma
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 175 |
| Published | February 2024 |
| Forecast Period | 2024 - 2028 |
| Estimated Market Value ( USD | $ 2.31 Billion |
| Forecasted Market Value ( USD | $ 2.97 Billion |
| Compound Annual Growth Rate | 6.5% |
| Regions Covered | Global |
| No. of Companies Mentioned | 30 |
